ABBVIE'S TELISOTUZUMAB ADIZUTECAN (TEMAB-A) RECEIVES TWO BREAKTHROUGH THERAPY DESIGNATIONS FROM THE U.S. FDA FOR CRC AND NSCLC

Reuters · 1d ago

Please log in to view news